Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company's lead candidate is MGL-3196, an orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) ß-selective agonist, which is in Phase II clinical trials for the treatment of non-alcoholic steatohepatitis and heterozygous familial hypercholesterolemia. It is also developing MGL-3745, a THR-ß-selective small molecule that is in preclinical trials. The company has research, development, and commercialization agreement with Hoffmann-La Roche to develop, use, sell, offer for sale, and import various licensed products. Madrigal Pharmaceuticals, Inc. was founded in 2011 and is headquartered in West Conshohocken, Pennsylvania.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:MDGL
CUSIP87162T20
Phone484-380-9263
Debt
Debt-to-Equity RatioN/A
Current Ratio90.47
Quick Ratio90.47
Price-To-Earnings
Trailing P/E Ratio-75.92
Forward P/E Ratio-87.89
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$13.02 per share
Price / Book14.78
Profitability
EPS (Most Recent Fiscal Year)($2.54)
Net Income$-31,150,000.00
Net MarginsN/A
Return on Equity-13.17%
Return on Assets-12.74%
Miscellaneous
Employees8
Outstanding Shares15,370,000
Market Cap$3.18 billion
Madrigal Pharmaceuticals (NASDAQ:MDGL) Frequently Asked Questions
What is Madrigal Pharmaceuticals' stock symbol?
Madrigal Pharmaceuticals trades on the NASDAQ under the ticker symbol "MDGL."
How were Madrigal Pharmaceuticals' earnings last quarter?
Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) announced its quarterly earnings results on Tuesday, August, 7th. The biopharmaceutical company reported ($0.45) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.63) by $0.18. View Madrigal Pharmaceuticals' Earnings History.
When is Madrigal Pharmaceuticals' next earnings date?
What price target have analysts set for MDGL?
10 equities research analysts have issued 1-year price objectives for Madrigal Pharmaceuticals' shares. Their forecasts range from $281.00 to $400.00. On average, they expect Madrigal Pharmaceuticals' share price to reach $321.1429 in the next twelve months. This suggests a possible upside of 66.8% from the stock's current price. View Analyst Price Targets for Madrigal Pharmaceuticals.
What is the consensus analysts' recommendation for Madrigal Pharmaceuticals?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Madrigal Pharmaceuticals in the last year. There are currently 3 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Madrigal Pharmaceuticals.
Who are some of Madrigal Pharmaceuticals' key competitors?
Some companies that are related to Madrigal Pharmaceuticals include Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Sarepta Therapeutics (SRPT), Nektar Therapeutics (NKTR), Bausch Health Companies (BHC), Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), Valeant Pharmaceuticals (VRX), Beigene (BGNE), Ionis Pharmaceuticals (IONS), Alkermes (ALKS), Catalent (CTLT), Amarin (AMRN), Dr.Reddy's Laboratories (RDY) and SAGE Therapeutics (SAGE).
Who are Madrigal Pharmaceuticals' key executives?
Madrigal Pharmaceuticals' management team includes the folowing people:
- Dr. Paul A. Friedman, Chairman, Pres & CEO (Age 75)
- Mr. Marc R. Schneebaum, Sr. VP & CFO (Age 64)
- Dr. Rebecca A. Taub, Founder, Exec. VP of R&D, Chief Medical Officer and Director (Age 66)
Who are Madrigal Pharmaceuticals' major shareholders?
Madrigal Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Capital Impact Advisors LLC (0.05%). Company insiders that own Madrigal Pharmaceuticals stock include Bay City Capital Llc, Marc R Schneebaum, Rebecca Taub and Richard S Levy. View Institutional Ownership Trends for Madrigal Pharmaceuticals.
Which institutional investors are buying Madrigal Pharmaceuticals stock?
How do I buy shares of Madrigal Pharmaceuticals?
Shares of MDGL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Madrigal Pharmaceuticals' stock price today?
One share of MDGL stock can currently be purchased for approximately $192.48.
How big of a company is Madrigal Pharmaceuticals?
Madrigal Pharmaceuticals has a market capitalization of $3.18 billion. The biopharmaceutical company earns $-31,150,000.00 in net income (profit) each year or ($2.54) on an earnings per share basis. Madrigal Pharmaceuticals employs 8 workers across the globe.
What is Madrigal Pharmaceuticals' official website?
How can I contact Madrigal Pharmaceuticals?
Madrigal Pharmaceuticals' mailing address is 200 BARR HARBOR DRIVE SUITE 400, WEST CONSHOHOCKEN PA, 19428. The biopharmaceutical company can be reached via phone at 484-380-9263 or via email at [email protected]
MarketBeat Community Rating for Madrigal Pharmaceuticals (NASDAQ MDGL)
MarketBeat's community ratings are surveys of what our community members think about Madrigal Pharmaceuticals and other stocks. Vote "Outperform" if you believe MDGL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MDGL will underperform the S&P 500 over the long term. You may vote once every thirty days.
